DETECT Fentanyl and Xylazine Act of 2024

Proposed 2024-06-07 | Official source

Summary

Amends the Homeland Security Act to enhance drug detection capabilities using AI, requiring research and development of equipment for law enforcement. Directs adherence to AI risk management guidelines and prioritization based on DEA threat reports.

This machine-generated summary is awaiting review by an AGORA editor. Use with caution.

Key facts

🏛️ This document was proposed and/or enacted by the United States Congress but is now defunct. For authoritative text and metadata, visit the official source.

📜 This document's name is Detection Equipment and Technology Evaluation to Counter the Threat of Fentanyl and Xylazine Act of 2024. AGORA also tracks this document under the name DETECT Fentanyl and Xylazine Act of 2024.

Themes AI risks, applications, governance strategies, and other themes addressed in AGORA documents.

Thematic tags are in progress.

Full text

This is an unofficial copy. The document has been archived and reformatted in plaintext for AGORA. Footnotes, tables, and similar material may be omitted. For the official text, visit the original source.

SECTION 1. SHORT TITLES. This Act may be cited as the “Detection Equipment and Technology Evaluation to Counter the Threat of Fentanyl and Xylazine Act of 2024” or the “DETECT Fentanyl and Xylazine Act of 2024”. SEC. 2. ENHANCING THE CAPACITY TO DETECT, IDENTIFY, AND DISRUPT DRUGS SUCH AS FENTANYL AND XYLAZINE. Section 302 of the Homeland Security Act of 2002 (6 U.S.C. 182) is amended— (1) in paragraph (13), by striking “and” at the end; (2) in paragraph (14), by striking the period at the end and inserting “; and”; and (3) by adding at the end the following: “(15) carrying out research, development, testing, evaluation, and cost-benefit analyses to improve the safety, effectiveness, and efficiency of equipment and reference libraries for use by Federal, State, local, Tribal, and territorial law enforcement agencies for the accurate detection of drugs or the disruption of drug trafficking for drugs such as fentanyl and xylazine, including, but not limited to— “(A) portable equipment that can detect and identify drugs with minimal or no handling of the sample; “(B) equipment that can separate complex mixtures containing low concentrations of drugs and high concentrations of cutting agents into their component parts to enable signature extraction for field identification and detection; and “(C) technologies that use machine learning or artificial intelligence (as defined in section 5002 of the National Artificial Intelligence Initiative Act of 2020 (15 U.S.C. 9401)) and other techniques to predict whether the substances in a sample are controlled substance analogues or other new psychoactive substances not yet included in available reference libraries.”.

SEC. 3. REQUIREMENTS. In carrying out section 302(15) of the Homeland Security Act of 2002, as added by section 2, the Under Secretary for Science and Technology shall— (1) follow the recommendations, guidelines, and best practices described in the Artificial Intelligence Risk Management Framework (NIST AI 100–1) or any successor document published by the National Institute of Standards and Technology; and (2) establish the Directorate of Science and Technology’s research, development, testing, evaluation, and cost-benefit analysis priorities under such section 302(15) based on the latest available information, including the latest State and Territory Report on Enduring and Emerging Threats published by the Drug Enforcement Administration or any successor document. Passed the House of Representatives September 9, 2024.